

1 **Bayesian forecasting for intravenous tobramycin dosing in adults with Cystic Fibrosis using one versus**  
2 **two serum concentrations in a dosing interval**

3 Philip G. Drennan<sup>1</sup>, Yann Thoma<sup>2</sup> PhD, Lucinda Barry<sup>3</sup>, Johan Matthey<sup>2</sup>, Sheila Sivam<sup>3,4</sup> PhD, Sebastiaan J.  
4 van Hal<sup>1,4</sup> PhD

5

6 <sup>1</sup>Department of Microbiology and Infectious Diseases, Royal Prince Alfred Hospital, Sydney, Australia

7 <sup>2</sup>School of Management and Engineering Vaud (HEIG-VD), University of Applied Science Western  
8 Switzerland (HES-SO), Yverdon-les-Bains, Switzerland

9 <sup>3</sup>Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia

10 <sup>4</sup>University of Sydney, Australia

11 Running title: Bayesian forecasting for intravenous tobramycin dosing in Cystic Fibrosis

12

13 Corresponding author: Philip Drennan, email address for correspondence: [pgdrennan@gmail.com](mailto:pgdrennan@gmail.com),  
14 phone +44 (0) 1865 221918

15 Current Affiliation: Oxford University Hospitals NHS Foundation Trust, Oxford, UK

16

17 **Abstract**

18 **Background**

19 Intravenous tobramycin requires therapeutic drug monitoring (TDM) to ensure safety and efficacy when  
20 used for prolonged treatment, as in infective exacerbations of Cystic Fibrosis (CF). The 24 hour area  
21 under the concentration time curve ( $AUC_{24}$ ) is widely used to guide dosing, however there remains  
22 variability in practice around methods for its estimation.

23 **Objectives**

24 To determine the potential for a sparse sampling strategy using a single post-infusion tobramycin  
25 concentration and Bayesian forecasting, to assess the  $AUC_{24}$  in routine practice.

26 **Methods**

27 Adults with CF receiving once daily tobramycin had paired concentrations measured 2 hours ( $c_1$ ) and 6  
28 hours ( $c_2$ ) following end of infusion as routine monitoring. We estimated  $AUC_{24}$  exposures using Tucuxi,  
29 a Bayesian forecasting application incorporating a validated population pharmacokinetic model. We  
30 performed simulations to estimate  $AUC_{24}$  using the full dataset using  $c_1$  and  $c_2$ , compared to estimates  
31 using depleted datasets ( $c_1$  or  $c_2$  only), with and without concentration data from earlier in the course.  
32 We assessed agreement between each simulation condition and the reference graphically, and  
33 numerically using median difference ( $\Delta$ )  $AUC_{24}$ , and (relative) root mean square error (rRMSE) as  
34 measures of bias and accuracy respectively.

35 **Results**

36 55 patients contributed 512 concentrations from 95 tobramycin courses and 256 TDM episodes. Single  
37 concentration methods performed well, with median  $\Delta AUC_{24} < 2 \text{ mg}\cdot\text{h}\cdot\text{l}^{-1}$  and rRMSE of  $< 15\%$  for  
38 sequential  $c_1$  and  $c_2$  conditions.

39 **Conclusions**

40 Bayesian forecasting, using single post-infusion concentrations taken 2-6 hours following tobramycin  
41 administration can adequately estimate true exposure in this patient group and are suitable for routine  
42 TDM practice.

43

44 **Key Points**

- 45 - In stable adult patients with Cystic fibrosis without significant renal impairment, Bayesian  
46 forecasting allows accurate estimation of tobramycin AUC<sub>24</sub> using a single blood sample taken 2-  
47 6 hours post-infusion with acceptable accuracy, especially when including prior measured  
48 concentrations.
- 49 - A single sample approach with Bayesian forecasting is logistically less complicated than a two-  
50 sample approach, and could facilitate best-practice TDM in the outpatient setting.
- 51 - A more intensive sampling strategy with Bayesian forecasting using two tobramycin  
52 concentrations in a dosing interval should be considered in unstable patients, or where  
53 observed concentrations deviate significantly from model predictions.

54

55 **Declarations**

56 **Authors' contributions** PD conceived the study, assisted with data collection and analysed the data and  
57 drafted the manuscript. LB collected the data and reviewed the manuscript. YT and JM performed the  
58 simulations and reviewed the manuscript. SS supported development of the TDM service and data  
59 collection, and reviewed the manuscript. SVH conceived the study and reviewed the manuscript.

60 **Funding** No sources of funding were used in the preparation of this article

61 **Conflicts of interest** The authors have no conflicts of interest to declare

62 **Availability of data and material** Data requests should be submitted to the corresponding author.

63 Access to de-identified data stored on the synapse.org repository may be granted to suitably qualified

64 researchers following review.

65

66

67

68 **1. Introduction**

69 Life expectancy for patients with Cystic Fibrosis (CF) continues to improve, owing to a range of strategies  
70 to maintain lung function, including aggressive treatment of infective pulmonary exacerbations due to  
71 *Pseudomonas aeruginosa*.(1) Intravenous tobramycin is commonly prescribed for this purpose.(2) Well-  
72 known toxicities of tobramycin include nephrotoxicity and ototoxicity, and there is increasing interest in  
73 minimising these long-term sequelae, which are at least partly attributable to cumulative lifetime  
74 exposure.(2–4) Once-daily tobramycin dosing is increasingly becoming standard practice in many CF  
75 centres, however centres differ with regard to therapeutic drug monitoring (TDM) practices, which  
76 range from simple trough concentration and nomogram methods, to more direct monitoring of the 24  
77 hour area under the concentration time curve ( $AUC_{24}$ ). (5–7) At our centre (Royal Prince Alfred Hospital,  
78 Sydney, Australia), we perform  $AUC_{24}$  based monitoring (target  $AUC_{24}$  100 mg.h.l<sup>-1</sup>) using a log-linear  
79 regression (LLR) method, which requires two-concentrations within a dosing interval and simple  
80 pharmacokinetic calculations coded into a Microsoft Excel spreadsheet.(8) Although simple and  
81 accurate, significant attention is required to coordinate correct application of the TDM protocol,  
82 including obtaining two blood samples at the appropriate times, and ensuring the dosing and monitoring  
83 information is recorded accurately.(9,10) Thereafter, clinicians performing the  $AUC_{24}$  estimation must  
84 perform the required calculations in a timely manner in order to return dosing advice prior to the next  
85 dose. There is increasing interest in the ambulatory management of pulmonary exacerbations, however  
86 it is difficult and impractical to collect two post-infusion blood samples in the outpatient setting. A  
87 simple, accurate method of  $AUC_{24}$  estimation to inform ongoing dosing using a single blood sample may  
88 therefore greatly increase the efficiency of this TDM practice, broaden its utility to outpatient settings,  
89 and improve patient acceptability.

90 Bayesian forecasting, which incorporates information from population pharmacokinetic models with  
91 one or two measured post-infusion concentrations has been shown to accurately characterise  
92 tobramycin pharmacokinetics in adults with CF, compared to results derived from intensive  
93 sampling.(11,12) In a small study of 12 adults receiving once-daily tobramycin, Bayesian methods  
94 resulted in less biased and more precise  $AUC_{24}$  estimation than a LLR method, and one- and two-sample  
95 Bayesian strategies were similarly accurate.(11) The authors of this study considered all three methods  
96 potentially suitable for routine TDM. The aim of the current study was to examine the potential  
97 generalisability of this finding by studying a larger group of adult patients, representative of those  
98 typically managed in CF centres. We sought to determine the agreement in  $AUC_{24}$  estimation between a  
99 one-sample and a two-sample approach using Bayesian forecasting, in order to determine the potential  
100 suitability of a one-sample Bayesian forecasting approach for routine TDM in this group of patients.

101

## 102 **2. Methods**

### 103 **2.1. Patients and data**

104 We collected data retrospectively from adults (>18 years) with CF who received once-daily intravenous  
105 tobramycin for pulmonary exacerbations, as part of routine practice between January and December  
106 2018. Clinical staff were instructed to take blood samples for the measurement of tobramycin  
107 concentrations at two time points (hereafter designated  $t_1$  and  $t_2$ ) at approximately 2 hours ( $c_1$ ) and 6-8  
108 hours ( $c_2$ ) following the end of the infusion (0.5 hours). Dosing and drug concentration information, in  
109 addition to a patient's height, weight, and the most recent creatinine measurement, was submitted to  
110 the TDM monitoring service for estimation of pharmacokinetic parameters and subsequent dosing  
111 advice, in order to achieve a target  $AUC_{24}$  of 100mg/L (acceptable range 80-120mg.h.l<sup>-1</sup>). In routine  
112 practice our TDM service currently uses a log linear regression method for  $AUC_{24}$  estimation, with  
113 proportional dose adjustment for subsequent dose recommendations.(8)

114 We recruited all patients with CF contributing at least one pair of tobramycin concentrations, which  
115 constituted a single TDM episode. We excluded episodes where  $c_2$  was below the lower limit of  
116 quantification, and where any of the concentration measurements was considered unreliable based on  
117 clinician assessment at the time of the TDM episode—for example where  $c_1$  was higher than  $c_2$ . These  
118 cases were identified by the clinician performing the TDM, and prompted a request to repeat the  
119 measurements the following day.

120 The study was approved by the Sydney Local Health District Ethics Committee (ref X19-0168) with a  
121 waiver of informed consent due to retrospective collection of routinely collected data.

## 122 **2.2. Tobramycin assay**

123 Plasma tobramycin concentrations were determined using immune spectrophotometric assay on a  
124 Roche/Hitachi cobas c system platform with LLOQ of 0.33 mg l<sup>-1</sup> and intra- and inter-day assay  
125 coefficients of variation <10%.

## 126 **2.3. Simulation of sampling regimens**

127 We simulated the potential effect of different sparse-sampling strategies on PK parameter and AUC<sub>24</sub>  
128 estimates using the Tucuxi Bayesian forecasting software ([www.tucuxi.ch](http://www.tucuxi.ch)), using a previously validated  
129 population pharmacokinetic model for adults with CF by Hennig et al.(12–14) Patient age, height,  
130 weight, and serum creatinine were covariates for the underlying population pharmacokinetic model  
131 used to generate the *a priori* pharmacokinetic parameter estimates. We used the full set of sequential  
132 concentration pairs ( $S_{c_1c_2}$ ) available at the time of each TDM episode as the reference ('REF'), and  
133 compared this to one of five simulated sampling conditions ('SIM') which incorporated less information:  
134 a)  $c_1$  and  $c_2$  without sequential prior concentration measurements from the same TDM episode ( $NS_{c_1c_2}$ ),  
135 b)  $c_1$  measurements only, using sequential information from previous  $c_1$  measurements ( $S_{c_1}$ ); c)  $c_1$   
136 measurements only, without prior sequential measurements ( $NS_{c_1}$ ); d)  $c_2$  measurements only, with

137 sequential measurements ( $S_{c2}$ ; e)  $c_2$  measurements only, without sequential measurements ( $NS_{c2}$ ). We  
138 used customised scripts to perform the simulations using the Tucuxi engine, to reduce the risk of errors  
139 and to ensure reproducibility of the results.

#### 140 **2.4. Statistical analysis and measures of agreement**

141 We performed statistical analysis using R (version 3.3.2, R Foundation for Statistical Computing, Vienna,  
142 Austria) implemented in the RStudio environment (version 1.0.136, RStudio Team (2016), RStudio, Inc.,  
143 Boston, MA). As a measure of bias we estimated agreement of the PK parameters, and  $AUC_{24}$  between  
144 the reference and each of the simulated conditions for each TDM episode. The main parameter of  
145 interest was the estimated  $AUC_{24}$ , calculated from the estimated clearance and the administered dose  
146 according to equation (1):

$$147 \quad AUC_{24} = \frac{\text{dose per 24h}}{CL} \quad (1)$$

148 We calculated absolute differences in  $AUC_{24}$  estimates between each of the simulation conditions and  
149 the reference method according to equation (2):

$$150 \quad \Delta AUC_{24(SIM_m - REF)} (mg \cdot h \cdot l^{-1}) = AUC_{24(SIM_m)_{i,j}} - AUC_{24(REF)_{i,j}} \quad (2)$$

151 The relative difference in exposure estimates was calculated as per equation (3):

$$152 \quad \Delta AUC_{24(SIM_m - REF)} (\%) = \frac{AUC_{24(SIM_m)_{i,j}} - AUC_{24(REF)_{i,j}}}{(AUC_{24(SIM_m)_{i,j}} + AUC_{24(REF)_{i,j}})/2} \times 100\% \quad (3)$$

153 Where  $AUC_{24(SIM_m)_{i,j}}$  denotes the estimated  $AUC_{24}$  calculated using data from simulation  $m$  ( $NS_{c1c2}$ ,  
154  $NS_{c1}$ ,  $S_{c1}$ ,  $NS_{c2}$ ,  $S_{c2}$ ) for the  $i$ th individual on the  $j$ th TDM episode, and  $AUC_{24(REF)_{i,j}}$  denotes the  
155 estimated  $AUC_{24}$  calculated using the all prior concentration data available for individual  $i$  at the time of  
156 the  $j$ th TDM episode. For the purposes of this study separate admissions were treated as independent  
157 cases.



158 As a measure of accuracy of the simulated method with the reference we calculated the root mean  
159 square error (RMSE,  $mg \cdot h \cdot l^{-1}$ ) and the relative RMSE (rRMSE, %) according to equations (4), and (5):

$$160 \quad RMSE(mg \cdot h \cdot l^{-1}) = \sqrt{\frac{1}{n} \sum_{i,j=1}^n \left( AUC_{24(SIM_m)_{i,j}} - AUC_{24(REF)_{i,j}} \right)^2} \quad (4)$$

$$161 \quad rRMSE(\%) = \sqrt{\frac{1}{n} \sum_{i,j=1}^n \left( \frac{AUC_{24(SIM_m)_{i,j}} - AUC_{24(REF)_{i,j}}}{\frac{AUC_{24(SIM_m)_{i,j}} + AUC_{24(REF)_{i,j}}}{2}} \right)^2} \times 100\% \quad (5)$$

162 Where n is the total number of TDM episodes. We explored agreement of simulated conditions with the  
163 reference overall, and according to number of previous TDM episodes graphically, using boxplots and  
164 relative difference plots.(15)

## 165 Results

### 166 2.5. Patients and data

167 Between January 1st and December 21<sup>st</sup> 2018, 54 patients were admitted on 95 occasions for an  
168 infective exacerbation of their CF and received a course of tobramycin as part of their antimicrobial  
169 therapy. There were 256 TDM episodes (range 1-5 per course) and 512 concentrations. The median age  
170 was 31 years (IQR 22-40.25), and 23 (43%) patients were male. Tobramycin was given for a median 13  
171 days (IQR 11-14). Demographics are summarised in table 1. Dosing and monitoring data, and  
172 pharmacokinetic parameter estimates for each TDM episode are shown in table 2 and figure 1. The  
173 median dose of tobramycin was 8.6  $mg \cdot kg^{-1}$  (IQR 7.1-10). Within a dosing interval,  $c_1$  was measured at a  
174 median of 2 h (IQR 2 – 2.6), and  $c_2$  at a median of 6.2 h (IQR 6-6.7). Across all TDM episodes the median  
175 estimated  $AUC_{24}$  using the Bayesian forecasting approach with all available data was 94.2  $mg \cdot h \cdot L^{-1}$  (IQR  
176 75.3-112.9).

### 177 2.6. Comparison of simulation methods

178 Figure 2 shows the relative difference plot of  $\Delta AUC_{24}$  (%) for each of the simulation conditions. There  
179 was no clear trend in agreement according to estimated  $AUC_{24}$ . Table 3 and figure 3 show the estimated  
180 tobramycin exposure for the reference condition based on the full data set ( $S_{c_1c_2}$ ) and each of the  
181 simulation conditions, and differences between the methods, pooled across all TDM episodes ( $n=256$ ).  
182  $AUC_{24}$  estimates were on average modestly greater than the reference condition, with median  $\Delta AUC_{24}$   
183  $<5\%$  compared to  $S_{c_1c_2}$  for all conditions except  $NS_{c_1}$ . rRMSE of all methods was  $<15\%$  of the reference  
184  $AUC_{24}$ . Large differences in estimated exposure, defined arbitrarily as  $\Delta AUC_{24} > 30\%$  were rare in all  
185 conditions but occurred least frequently in the  $S_{c_1}$  condition (1.6% of episodes). Table 4 and figure 4  
186 show comparisons of  $NS_{c_1c_2}$ ,  $S_{c_1}$ , and  $S_{c_2}$  with the reference condition, stratified by TDM episode. As  
187 expected for  $NS_{c_1c_2}$ , both  $\Delta AUC_{24}$  and rRMSE increased for subsequent TDM episodes, as this condition  
188 only considered the most recent available data. For  $S_{c_1}$  and  $S_{c_2}$ , rRMSE improved modestly for second  
189 and subsequent TDM episodes, and was  $<15\%$  for all TDM episodes

## 190 Discussion

191 Our study suggests that in stable adult patients with CF pulmonary exacerbations, the tobramycin  $AUC_{24}$   
192 can be reliably estimated using Bayesian forecasting and a single post infusion concentration. In a small  
193 proportion of cases the estimates differed more significantly. The reasons for these outliers are unclear  
194 but could relate to erroneous information (e.g. time of dose or blood sample recorded incorrectly), or  
195 physiological instability. This observations illustrates the importance of attention to situations where  
196 observed concentrations are significantly different from those predicted by the model, in order to apply  
197 clinical judgement in when unexpected results occur. The graphical interface provided by modern  
198 Bayesian forecasting software allows a visual representation of this discrepancy, which may improve the  
199 identification of unusual results. Where observed concentrations deviate substantially from those  
200 predicted by the model, patients may benefit from repeat or more intensive sampling to confirm  
201 observed concentrations and to ensure an accurate estimation of their pharmacokinetic parameters.

202 This approach would be particularly applicable to critically unwell patients, given known physiological  
203 fluctuations in these patients where a single sample approach may be less appropriate.(16–19).

204 Similarly, in stable patients, significantly discrepant concentrations from those expected either relative  
205 to previous estimates or predicted on the population pharmacokinetics should prompt careful  
206 consideration of a pre-analytical source of error.(20)

207 Although a more limited sampling approach resulted in less accurate pharmacokinetic parameter  
208 estimation relative to the reference, the effect was usually small (rRMSE <15%). Although there is no  
209 established standard for acceptable accuracy in this context, it is of comparable magnitude to accepted  
210 target ranges used in clinical practice.(12) In specific situations, e.g. those at higher risk of renal  
211 dysfunction, or unstable patients with sepsis or requiring ICU admission, a more stringent approach may  
212 be considered appropriate. In these situations, clinicians may choose to monitor the patient more  
213 closely, e.g. by continuing with two-concentration monitoring until the patient is judged stable, and then  
214 switching to a single concentration approach, e.g. to reduce phlebotomy or line access, or to facilitate  
215 ambulatory management.

216 Accuracy and bias of estimates were similar whether using a sample taken approximately 2 hours after  
217 the end of the infusion or approximately 6 hours after the end of infusion. These results largely agree  
218 with the results of Gao et al, who found that a single concentration taken 70 – 640 minutes yielded  
219 sufficiently accurate results.(10) For practical purposes a timed blood sample taken any time between 2-  
220 6 hours post end of infusion is likely to be sufficient for routine monitoring.

221 Numerous software applications for performing Bayesian forecasting are now available, however have  
222 not yet been widely-adopted, possibly owing to access to and cost of specialist software, required  
223 expertise, and the switching cost of new TDM workflows.(7,21–23) The simplicity of a single-sample  
224 Bayesian forecasting method may therefore help to offset some of these barriers for adoption. Patients

225 with CF have generally stable tobramycin pharmacokinetics over time, and as such may be considered  
226 ideal candidates for Bayesian forecasting methods, which allow accumulation of data for an individual  
227 patient over time.(24) Patients with CF are frequently managed in CF centres and may have multiple  
228 admissions to the same institution, thus in theory clinicians managing these patients should be able to  
229 derive an accurate individualised dosing strategy for each patient. Bayesian forecasting software which  
230 allows automated population of results from an electronic medical record may therefore be of great  
231 benefit.

### 232 **3. Conclusions**

233 Bayesian forecasting, using a single post infusion sample between 2-6 hours post infusion and prior  
234 concentration measurements can precisely and accurately estimate tobramycin exposure. This simple  
235 approach increases the flexibility of a Bayesian TDM workflow, and may facilitate efficient outpatient  
236 monitoring for ambulatory therapy.

237

238

239

240

241

242 **4. References**

- 243 1. Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimates of survival  
244 for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient  
245 registry data. *J Cyst Fibros Off J Eur Cyst Fibros Soc.* 2018;17(2):218–27.
- 246 2. Prayle A, Smyth AR. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. *Curr*  
247 *Opin Pulm Med.* 2010 Nov;16(6):604–10.
- 248 3. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic  
249 fibrosis patients due to repeated intravenous aminoglycoside use. *Pediatr Pulmonol.* 2005  
250 Jan;39(1):15–20.
- 251 4. Garinis AC, Cross CP, Srikanth P, Carroll K, Feeney MP, Keefe DH, et al. The cumulative effects of  
252 intravenous antibiotic treatments on hearing in patients with cystic fibrosis. *J Cyst Fibros.* 2017 May  
253 1;16(3):401–9.
- 254 5. Prescott WA. A survey of extended-interval aminoglycoside dosing practices in United States adult  
255 cystic fibrosis programs. *Respir Care.* 2014 Sep;59(9):1353–9.
- 256 6. Soulsby N, Bell S, Greville H, Doecke C. Intravenous aminoglycoside usage and monitoring of  
257 patients with cystic fibrosis in Australia. What's new? *Intern Med J.* 2009 Aug;39(8):527–31.
- 258 7. Paviour S, Hennig S, Staatz CE. Usage and monitoring of intravenous tobramycin in cystic fibrosis in  
259 Australia and the UK. *J Pharm Pract Res.* 46(1):15–21.
- 260 8. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. *Br J Clin*  
261 *Pharmacol.* 1995 Jun 1;39(6):605–9.
- 262 9. Nezic L, Derungs A, Bruggisser M, Tschudin-Sutter S, Krähenbühl S, Haschke M. Therapeutic drug  
263 monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of  
264 the optimal blood sampling strategy. *Eur J Clin Pharmacol.* 2014 Jul;70(7):829–37.
- 265 10. Gao Y, Hennig S, Barras M. Monitoring of Tobramycin Exposure: What is the Best Estimation  
266 Method and Sampling Time for Clinical Practice? *Clin Pharmacokinet.* 2018 Aug 24;
- 267 11. Barras MA, Serisier D, Hennig S, Jess K, Norris RLG. Bayesian Estimation of Tobramycin Exposure in  
268 Patients with Cystic Fibrosis. *Antimicrob Agents Chemother.* 2016 Oct 21;60(11):6698–702.
- 269 12. Burgard M, Sandaradura I, van Hal SJ, Stacey S, Hennig S. Evaluation of Tobramycin Exposure  
270 Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in  
271 Children and Adults with Cystic Fibrosis. *Clin Pharmacokinet.* 2017 Nov 13;
- 272 13. Hennig S, Standing JF, Staatz CE, Thomson AH. Population pharmacokinetics of tobramycin in  
273 patients with and without cystic fibrosis. *Clin Pharmacokinet.* 2013 Apr;52(4):289–301.
- 274 14. Dubovitskaya A, Buclin T, Schumacher M, Aberer K, Thoma Y. TUCUXI: An Intelligent System for  
275 Personalized Medicine from Individualization of Treatments to Research Databases and Back. In

- 276 ACM Press; 2017 [cited 2018 Aug 8]. p. 223–32. Available from:  
277 <http://dl.acm.org/citation.cfm?doid=3107411.3107439>
- 278 15. Pollock MA, Jefferson SG, Kane JW, Lomax K, MacKinnon G, Winnard CB. Method comparison--a  
279 different approach. *Ann Clin Biochem*. 1992 Sep;29 ( Pt 5):556–60.
- 280 16. Reimann IR, Meier-Hellmann A, Traut T, Reinhart K, Hoffmann A. Monitoring of a single post-  
281 infusion blood sample to estimate the actual peak and trough concentration of tobramycin in  
282 critically ill patients. *Exp Toxicol Pathol Off J Ges Toxikol Pathol*. 2003 Jun;54(5–6):493–8.
- 283 17. Denaro CP, Ravenscroft PJ. Comparison of Sawchuk-Zaske and Bayesian forecasting for  
284 aminoglycosides in seriously ill patients. *Br J Clin Pharmacol*. 1989 Jul;28(1):37–44.
- 285 18. Rodvold KA, Blum RA. Predictive performance of Sawchuk-Zaske and Bayesian dosing methods for  
286 tobramycin. *J Clin Pharmacol*. 1987 Jun;27(5):419–24.
- 287 19. Conil J-M, Georges B, Ruiz S, Rival T, Seguin T, Cougot P, et al. Tobramycin disposition in ICU patients  
288 receiving a once daily regimen: population approach and dosage simulations. *Br J Clin Pharmacol*.  
289 2011 Jan;71(1):61–71.
- 290 20. Prescott WA, Mancuso MA. Clinical impact of laboratory error on therapeutic drug monitoring of  
291 once-daily tobramycin in cystic fibrosis: Case series. *SAGE Open Med Case Rep*.  
292 2014;2:2050313X14521158.
- 293 21. Drennan P, Doogue M, van Hal SJ, Chin P. Bayesian therapeutic drug monitoring software: past,  
294 present and future. *Int J Pharmacokinet [Internet]*. 2018 Dec 12 [cited 2018 Dec 13]; Available from:  
295 <https://www.future-science.com/doi/10.4155/ipk-2018-0005>
- 296 22. Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring  
297 software: a review of available computer tools. *Clin Pharmacokinet*. 2013 Jan;52(1):9–22.
- 298 23. Kumar AA, Burgard M, Stacey S, Sandaradura I, Lai T, Coorey C, et al. An evaluation of the user-  
299 friendliness of Bayesian forecasting programs in a clinical setting. *Br J Clin Pharmacol*.  
300 2019;85(10):2436–41.
- 301 24. Alghanem S, Paterson I, Touw DJ, Thomson AH. Influence of multiple courses of therapy on  
302 aminoglycoside clearance in adult patients with cystic fibrosis. *J Antimicrob Chemother*. 2013 Jun  
303 1;68(6):1338–47.


304

305

306

307 **Figures**


308 **Figure 1:** Time versus tobramycin concentration (n=512)



309

310

311 **Figure 2:** Relative difference plot of mean estimated  $AUC_{24}$  versus difference in  $AUC_{24}$  (%) for the  
312 reference method (full dataset) versus each simulated condition, with median difference and 2.5<sup>th</sup> and  
313 97.5<sup>th</sup> percentiles (dashed lines)




314

315




316 **Figure 3:** Distribution of differences in estimated  $AUC_{24}$  (%) for full data set (reference condition) versus  
317 each simulation condition



318

319

320 **Figure 4:** Distribution of differences in estimated  $AUC_{24}$  for full dataset (reference condition) versus  
321 selected simulation conditions according to TDM episode



322

323

Table 1: Baseline demographics and admissions

Patients	54
Age (years), median (IQR)	31 (22, 40.3)
Male, n (%)	23 (42.6)
Height (cm), median (IQR)	166 (160, 171)
Weight (kg), median (IQR)	56 (50, 65)
Admissions/patient, median (range)	1 (1, 6)
Admissions, total	95
Creatinine on admission (umol/L), median (IQR)	64 (53, 77)
CRP on admission (mg/L), median (IQR)	28 (7.9, 64.8)
T>38C on admission, n (%)	13 (14.1)
Length of tobramycin course (days), median (IQR)	13 (11, 14)

324

325

Table 2: Tobramycin concentrations and parameter estimates for each TDM episode (n=256)

Measurement/parameter estimate	Median (IQR)
Dose administered (mg)	520.0 (400, 560)
Dose per kg (mg.kg <sup>-1</sup> )	8.6 (7.1, 10)
t <sub>1</sub> (h)	2.0 (2, 2.2)
t <sub>2</sub> (h)	6.2 (6, 6.7)
c <sub>1</sub> (mg.L <sup>-1</sup> )	11.5 (9.3, 14)
c <sub>2</sub> (mg.L <sup>-1</sup> )	2.9 (2.2, 3.9)
V <sub>1</sub> (L.70kg <sup>-1</sup> )	18.4 (15, 21.5)
V <sub>2</sub> (L.70kg <sup>-1</sup> )	8.9 (7.9, 10)
Q (L.h <sup>-1</sup> .70kg <sup>-1</sup> )	1.5 (1.3, 1.8)
CL (L.h <sup>-1</sup> .70kg <sup>-1</sup> )	6.2 (5.4, 7.5)
AUC <sub>24</sub> (mg.h.l <sup>-1</sup> )	94.2 (75.3, 112.9)

326

Table 3: Comparison of simulation conditions

Simulation condition	AUC <sub>24</sub> (mg.h.l <sup>-1</sup> )	ΔAUC <sub>24</sub> (mg.h.l <sup>-1</sup> )	ΔAUC <sub>24</sub> (%)	ΔAUC <sub>24</sub> >30%	RMSE (mg.h.l <sup>-1</sup> )	rRMSE (%)
Sc1c2	94.2 (75.3, 112.9)	(ref)				
NSc1c2	95.9 (76.6, 118.1)	0.0 (0, 7.2)	0.0 (0, 7.6)	8 (3.2)	12.3	10.9
Sc1	96.8 (79.4, 112.5)	1.6 (-3.6, 7.1)	1.7 (-3.3, 8.4)	4 (1.6)	11.3	11.1
NSc1	97.8 (79.2, 119.8)	4.9 (-0.6, 13)	5.3 (-0.7, 13.6)	9 (3.6)	16.7	14.2
Sc2	95.5 (75.2, 116.8)	1.2 (-3.7, 6.7)	1.8 (-4.4, 6.8)	7 (2.8)	13.1	11.4
NSc2	96.0 (74.7, 119.1)	3.1 (-3.7, 9.5)	3.5 (-4.5, 10.5)	7 (2.8)	15.5	13.0

Data are expressed as median (IQR) or n (%)

327

328

Table 4: Comparison of simulation conditions according to number of preceding TDM episodes

Simulation condition	TDM episode	$\Delta AUC_{24}$ (mg.h.l <sup>-1</sup> )	$\Delta AUC_{24}$ (%)	RMSE (mg.h.l <sup>-1</sup> )	rRMSE (%)
NSc1c2	first	0.0 (0, 0)	0.0 (0, 0)	0.0	0.0
	second	2.7 (-3.2, 7.8)	3.3 (-3.2, 8.7)	12.2	11.7
	third or greater	8.1 (-0.5, 18.4)	8.3 (-0.5, 14.8)	19.1	16.1
Sc1	first	3.1 (-1.6, 10.2)	5.0 (-2, 12.1)	12.8	13.0
	second	1.3 (-4.1, 5.6)	1.4 (-3.5, 6)	10.8	9.9
	third or greater	-0.7 (-5.6, 4.3)	-0.7 (-5.9, 3.8)	9.6	9.4
Sc2	first	0.2 (-6.2, 4.3)	0.6 (-7.3, 5.8)	11.8	11.6
	second	1.1 (-2.7, 8.2)	1.9 (-2.8, 7.7)	14.7	11.5
	third or greater	2.3 (-1.4, 9.3)	2.5 (-1.3, 10)	12.8	11.1

Data are expressed as median (IQR)

329

330

331

332

333

334

335

336

337